Skip to main content
SpringerLink
Log in
Book cover

Handbook of Non-Motor Symptoms in Parkinson's Disease pp 45–56Cite as

Neuropsychiatric symptoms

  • Chapter
  • First Online:

Abstract

Neuropsychiatric problems represent a major group of non-motor symptoms (NMSs) that require effective management. They can range from depression, anxiety, compulsive disorders and hallucinations to dementia, so they are a significant cause of disability and reduced health-related quality of life (HRQoL) for affected patients, and also substantially increase distress to caregivers [1]. It has been found that non-tremordominant Parkinson’s disease (PD) is associated with an increased risk of cognitive deterioration, depression, apathy and hallucinations compared with other motor subtypes of PD [2].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Löhle M, Storch A, Reichmann H. Beyond tremor and rigidity: non-motor features of Parkinson’s disease. J Neural Transm 2009;116:1483-1492.

    Google Scholar 

  2. Reijnders J, Ehrt U, Lousberg R, Aarsland D, Leentjens A. The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 2009;15:379-382.

    Google Scholar 

  3. Oguru M, Tachibana H, Toda K, Okuda B, Oka N. Apathy and depression in Parkinson’s disease. J Geriatr Psychiatry Neurol 2010;23:35-41.

    Google Scholar 

  4. Starkstein SE, Mayberg SE, Prezioso TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry 1992;4:134-139.

    Google Scholar 

  5. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;73:636-642.

    Google Scholar 

  6. Alves G, Wentzel-Larsen T, Jansen JP. Is fatigue and independent and persistent symptom in patients with Parkinson’s disease? Neurology 2004;63:1908-1911.

    Google Scholar 

  7. Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward and Parkinson’s disease: influence of L-dopa therapy. Neuropsychologia 2002;40:2257-2267.

    Google Scholar 

  8. Marin RS, Fogel BS, Hawkin J, et al. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23-30.

    Google Scholar 

  9. Chaudhuri K, Schapira A. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.

    Google Scholar 

  10. Brown RG, Pluck G. Negative symptoms: the ‘pathology’ of motivation and goal directed behavior. Trends Neurosci 2000;23:412-417.

    Google Scholar 

  11. Chaudhuri KR, Joseph H. Friedman, Erwin Surmann, et al; on behalf of the RECOVER study investigators. The effects of transdermal rotigotine on mood/cognition: interpretations from a post hoc analysis of the RECOVER Study using the Parkinson’s disease Non-Motor Symptom Scale. Poster presented at: 15th International Congress of Parkinson’s Disease and Movement Disorders; June 5-9, 2011; Toronto, Canada.

    Google Scholar 

  12. Nilsson FM, Kessig LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorders. Acta Psychiatr Scand 2001;104:380-386.

    Google Scholar 

  13. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 2001;14:120-124.

    Google Scholar 

  14. Funkiewiez A, Ardouin C, Caputo E, et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behavior in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:834-839.

    Google Scholar 

  15. Reichmann H, Schneider C, Löhle M. Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord 2009;15:S87-S92.

    Google Scholar 

  16. Shulman L. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002;8:193-197.

    Google Scholar 

  17. Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease. Loss of dopamine and noradrenaline innervations in the limbic system. Brain 2005;128:1314-1322.

    Google Scholar 

  18. Miyasaki J, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.

    Google Scholar 

  19. Corrigan M, Denahan AQ, Wright CE, et al. Comparison of pramipexole and placebo in patients with major depression. Depress Anxiety 2000;11: 58-65.

    Google Scholar 

  20. Reichmann H, Brech MH, Koster J. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs 2003;17:965-973.

    Google Scholar 

  21. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.

    Google Scholar 

  22. Goldberg J, Burdick KE, Endick CJ. Preliminary randomized placebo controlled trial to pramipexole added to mood stabilizers for treatment of resistant bipolar depression. Am J Psychiatry 2004;161:564-566.

    Google Scholar 

  23. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease. A national multicenter parallel group randomized study. J Neurol 2006;253:601-607.

    Google Scholar 

  24. Pahwa R, Stacy MA, Factor SA, et al; on behalf of the EASE-PD adjunct study investigators. Ropinirole 24-hour prolonged release: randomized controlled study in advanced Parkinson’s disease. Neurology 2007; 68:1108-1115.

    Google Scholar 

  25. Trenkwalder C, Kies B, Rudzinska M, et al, and the RECOVER study group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double-blind, randomised, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-99.

    Google Scholar 

  26. Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE. Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003;2:CD003465.

    Google Scholar 

  27. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson’s disease. Mov Disord 2009;24:1325-1332.

    Google Scholar 

  28. Menza M, Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.

    Google Scholar 

  29. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005;20:1161-1169.

    Google Scholar 

  30. Shiba M, Bower JH, Maragonare DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000;15:669-677.

    Google Scholar 

  31. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord 2003;18:646-651.

    Google Scholar 

  32. Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. J Neurol 2009;256:293-298.

    Google Scholar 

  33. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996;8:383-392.

    Google Scholar 

  34. Goetz C. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord 2010;25:S104-S109.

    Google Scholar 

  35. Singh A, Althoff R, Martineau J, Jacobson J. Pramipexole, ropinirole and mania in Parkinson’s disease. Am J Psychiatry 2005;162:814-815.

    Google Scholar 

  36. Witjas T, Kaphan E, Regis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease. Mov Disord 2007;22:1729-1734.

    Google Scholar 

  37. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 2008;7:605-614.

    Google Scholar 

  38. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997;244:2–8.

    Google Scholar 

  39. Uc E, Rizzo M, Anderson S, Qian S, Rodnitzky R, Dawson J. Visual dysfunction in Parkinson’s disease without dementia. Neurology 2005;65:1907-1913.

    Google Scholar 

  40. Williams-Gray C, Foltynie T, Brayne C, Robbins T, Barker R. Evolution of cognitive dysfunction in and incident Parkinson’s disease cohort. Parkinsonism Relat Disord 2007;13:1787-1798.

    Google Scholar 

  41. Emre M. What causes mental dysfunction in Parkinson’s disease? Mov Disord 2003a;18:S63-S71.

    Google Scholar 

  42. Rinne J, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease – F18 fluorodopa positron emission tomographic study. Arch Neurol 2000;57:470-475.

    Google Scholar 

  43. Lewis S, Dove A, Robbins T, Barker R, Owen A. Cognitive impairments in early Parkinson’s disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351-6356.

    Google Scholar 

  44. Cools R, Stefanova E, Barker R, Robbins T, Owen A. Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125:584-594.

    Google Scholar 

  45. Mattay V, Tessitore A, Callicott J, et al. Dopaminergic modulation of cortical function in patients with Parkinson’s disease. Ann Neurol 2002;51:156-164.

    Google Scholar 

  46. Aarsland D, Larsen J, Tandber E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.

    Google Scholar 

  47. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology, and risk factors. Brain 2000;123:733-745.

    Google Scholar 

  48. Papapetropoulos S, Mash D. Psychotic symptoms in Parkinson’s disease. From description to etiology. J Neurol 2005;252:753-764.

    Google Scholar 

  49. Diederich N, Pieri V, Goetz C. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord 2003;18:831-832.

    Google Scholar 

  50. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and new integrative model. Mov Disord 2005;20:130-140.

    Google Scholar 

  51. Onofrj M, Thomas A, D’Ándreamatteo G, et al. Incidence of RB D and hallucination in patients affected by Parkinson’s disease: 8 year follow-up. Neuro Sci 2002;23:S91-S94.

    Google Scholar 

  52. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.

    Google Scholar 

  53. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson’s disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol 2004;61:1280-1284.

    Google Scholar 

  54. Kipps CM, Fung VSC, Grattan-Smith P, de Moore GM, Morris JGL. Movement disorder emergencies. Mov Disord 2005;20:322-334.

    Google Scholar 

  55. Fenelon G. Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008;13:18-25.

    Google Scholar 

  56. Papapetropoulos S, Katzen H, Schrag A., Singer C, Scanlon B, Nation D. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol 2008;8:21.

    Google Scholar 

  57. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999;340:757-763.

    Google Scholar 

  58. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999;353:2041.

    Google Scholar 

  59. Fernandez H, Friedman J, Jacques C, Rosenfeld M. Quetiapine for the treatment of druginduced psychosis in Parkinson’s disease. Mov Disord 1999;14:484-487.

    Google Scholar 

  60. Fernandez H, Trieschmann ME, Burke MA, Friedmann JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515.

    Google Scholar 

  61. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18:510-514.

    Google Scholar 

  62. Dewey RB Jr, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2000;55:1753-1754.

    Google Scholar 

  63. Brandstaedter D, Oertel WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2002;58:160-161.

    Google Scholar 

  64. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.

    Google Scholar 

  65. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov Disord 2004;19:29-35.

    Google Scholar 

  66. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156.

    Google Scholar 

  67. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005;20:958-963.

    Google Scholar 

  68. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002;18:258-264.

    Google Scholar 

  69. Emre M, Aarsland D, Albanese A, et al. Rivastigmine in Parkinson’s disease patients with dementia: a randomized, double-blind, placebo-controlled study. N Engl J Med 2004;351:2509-2518.

    Google Scholar 

  70. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006;21:1899-1907.

    Google Scholar 

  71. Bergmann J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002;25:107-110.

    Google Scholar 

  72. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002;23:41-43.

    Google Scholar 

  73. Voon V, Potenza M, Thomsen T. Medication-induced impulse control and repetitive behaviors in Parkinson’s disease. Curr Opin Neurol 2007;20:484-442.

    Google Scholar 

  74. Weintraub D. Impulse control disorders in Parkinson’s disease: prevalence and possible risk factors. Parkinsonism Relat Disord 2009;15:S110-S113.

    Google Scholar 

  75. Evans A, Pavese N, Lawrence A. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.

    Google Scholar 

  76. Rabinak CA, Koester J, Potenza MN, et al. Dopamine agonist withdrawal syndrome in Parkinson’s disease. Arch Neurol 2010;67:58-63.

    Google Scholar 

  77. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005;20:1255-1263.

    Google Scholar 

  78. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.

    Google Scholar 

  79. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004;19:1043-1049.

    Google Scholar 

  80. Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003b;2:229-237.

    Google Scholar 

  81. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study on Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.

    Google Scholar 

  82. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008;70:1017-1022.

    Google Scholar 

  83. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2007;13:323-332.

    Google Scholar 

  84. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein immunoreative cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000;100:285-290.

    Google Scholar 

  85. Cummings J. Reconsidering diagnostic criteria for dementia with Lewy bodies: highlights from the Third International Workshop on Dementia with Lewy bodies and Parkinson’s disease dementia, September 17–20, 2003, Newcastle upon Tyne, UK. Rev Neurol Dis 2004;1:31-34.

    Google Scholar 

  86. Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson’s disease. Neurology 2004;62:2005-2009.

    Google Scholar 

  87. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.

    Google Scholar 

  88. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebocontrolled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004;19:1-8.

    Google Scholar 

  89. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.

    Google Scholar 

  90. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 2008;38:937-945.

    Google Scholar 

  91. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618.

    Google Scholar 

  92. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 2009;24:1217-1221.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Bremerhaven, Germany

    Per Odin

  2. Dementia Subunit of the Department of Neurology, Bremerhaven, Germany

    Kerstin Dietrich

Authors
  1. Per Odin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerstin Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Healthcare, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Odin, P., Dietrich, K. (2011). Neuropsychiatric symptoms. In: Handbook of Non-Motor Symptoms in Parkinson's Disease. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-60-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-60-9_5

  • Published:

  • Publisher Name: Springer Healthcare, Heidelberg

  • Print ISBN: 978-1-907673-23-8

  • Online ISBN: 978-1-908517-60-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation